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Abstract
Background: The predictive value of serum uric acid (SUA) for adverse cardiovascular events among obese and overweight
patients is not known, but potentially important because of the relation between hyperuricaemia and obesity.
Methods: The relationship between SUA and risk of cardiovascular adverse outcomes (nonfatal myocardial infarction,
nonfatal stroke, resuscitated cardiac arrest or cardiovascular death) and all-cause mortality, respectively, was evaluated in
a post-hoc analysis of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Participants enrolled in SCOUT were obese
or overweight with pre-existing diabetes and/or cardiovascular disease (CVD). Cox models were used to assess the role of
SUA as an independent risk factor.
Results: 9742 subjects were included in the study; 83.6% had diabetes, and 75.1% had CVD. During an average follow-up
time of 4.2 years, 1043 subjects had a primary outcome (myocardial infarction, resuscitated cardiac arrest, stroke, or
cardiovascular death), and 816 died. In a univariate Cox model, the highest SUA quartile was associated with an increased
risk of cardiovascular adverse outcomes compared with the lowest SUA quartile in women (hazard ratio [HR]: 1.59; 95%
confidence interval [CI]: 1.20–2.10). In multivariate analyses, adjusting for known cardiovascular risk factors the increased risk
for the highest SUA quartile was no longer statistically significant among women (HR: 0.99; 95% CI: 0.72–1.36) nor was it
among men. Analyses of all-cause mortality found an interaction between sex and SUA. In a multivariate Cox model
including women only, the highest SUA quartile was associated with an increased risk in all-cause mortality compared to the
lowest SUA quartile (HR: 1.51; 95% CI: 1.08–2.12). No relationship was observed in men (HR: 1.06; 95% CI: 0.82–1.36).
Conclusion: SUA was not an independent predictor of cardiovascular disease and death in these high-risk overweight/
obese people. However, our results suggested that SUA was an independent predictor of all-cause mortality in women.
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Introduction
The association of gout with cardiovascular disease, first
described in the 19th century was thought to be an association,
rather than a cause, of cardiovascular disease. More recent
evidence from cohort studies suggests a causal relationship
between hyperuricaemia and risk of adverse cardiovascular events
[1–4]. Some studies have only been able to show this for women
[5,6], while others have failed to demonstrate this association after
controlling for various well known atherosclerotic risk factors [7,8].
Because hyperuricemia is closely related to obesity, hyperten-
sion [9], and dyslipidaemia [10], it has been difficult to establish
whether or not an independent association between uric acid and
cardiovascular disease exists. Elevated uric acid might merely
represent an indirect marker of the metabolic syndrome. To
examine this question several studies have tested the effect of
allopurinol treatment on the risk of adverse cardiovascular events,
and high dose allopurinol seems to be associated with better
survival than low dose allopurinol, both in patients with congestive
heart failure [11] and in a general hospital patient population [12].
Most studies investigating the relationship between uric acid
and cardiovascular disease have included either healthy popula-
tions or patients with hypertension or congestive heart failure.
Hyperuricaemia does not form part of current definitions of the
cardio-metabolic syndrome [13–15], a syndrome closely associat-
ing overweight and obesity with adverse cardiovascular outcomes.
We have investigated the relationship between initial serum uric
acid concentration and risk of developing new cardiovascular
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events or mortality in a population of nearly 10,000 overweight or
obese, cardiovascular high risk patients.
Methods
The present analysis used data from the prospective SCOUT
(Sibutramine Cardiovascular OUTcomes) trial, a randomized,
double-blinded, placebo-controlled, multicentre clinical study with
sibutramine, a sympathomimetic agent used for weight loss.
SCOUT was conducted from January 2003 through March 2009
in 16 different countries in Europe, Australia and Latin America.
The primary study endpoint comprised a composite of nonfatal
myocardial infarction, nonfatal stroke, resuscitation after cardiac
arrest, and cardiovascular death (primary outcome events). A
secondary endpoint was all-cause mortality.
The details regarding the SCOUT trial have been described
elsewhere [16]. In brief, all patients in the trial were 55 years of
age or older, had body-mass index (BMI).27 kg/m2 and
,45 kg/m2, or a BMI.25 kg/m2 and ,27 kg/m2 plus a waist
circumference of at least 102 cm/88 cm (men/women). Another
criterion was a history of cardiovascular disease (defined as
a history of coronary artery disease, peripheral arterial occlusive
disease or stroke), or diabetes mellitus type 2 with at least one other
cardiovascular risk factor (defined as hypertension, dyslipidaemia,
current smoker, or diabetic nephropathy), or both. Because of
a lower than expected rate of primary outcome events, the
inclusion criteria changed after 15 months so that only the highest
risk patients were enrolled, i.e. patients with both a history of
cardiovascular disease and diabetes mellitus type 2 with one other
cardiovascular risk factor.
Medical conditions such as diabetes, hypertension and dyslipi-
daemia were to be treated as indicated by national guidelines
available at the time of this trial. Blood tests, including uric acid,
were performed at randomization baseline and annually thereaf-
ter. All blood tests were performed fasting, and were analysed in
a certified central laboratory.
Subjects were followed until their final visit, which was between
November 2008 and March 2009. For those subjects who
prematurely discontinued the study drug, follow up data were
obtained until March 2009 and analysed by the intention-to-treat
principle. For each of the separate the endpoints, patients were
censored after their first event.
We have divided the subjects into quartiles of uric acid
concentrations at baseline with separate cut off-points for men
and women, because women have lower SUA levels than men on
average. We investigated the overall rate of primary outcome
events, the rate of each component of the composite primary
outcome, and the rate of all-cause mortality.
Ethics
This study (Clinical Trial registration Number NCT00234832)
was approved be relevant local ethics committees and conducted
according to the Declaration of Helsinki. All participating subjects
had given their written informed consent prior to enrolment.
Statistics
Differences in continuous and discrete variables were compared
using analysis of variance and the Cochran-Armitage trend test,
respectively. Survival distribution function curves were constructed
using Kaplan-Meier methods.
We used Cox proportional hazard regression models to perform
univariate and multivariate analyses, stratifying for sex and
adjusting for the following factors: age, cholesterol, high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), BMI, glucose, triglycerides, creatinine, history of
only diabetes mellitus/diabetes mellitus and cardiovascular
disease/only cardiovascular disease, congestive heart failure,
systolic blood pressure, diastolic blood pressure, waist-hip ratio,
tobacco use, alcohol use, use of diuretics, use of beta-blockers, use
of statins, use of aspirin and randomized treatment (placebo vs.
sibutramine). Hazard ratios (HR) and their corresponding 95%
confidence intervals (CI) for uric acid quartiles were constructed
within the framework of the Cox models. Two-way interactions
between baseline uric acid level (i.e. values at the time of
randomization) and age, sex, BMI, glucose level, congestive heart
failure, diabetes mellitus, systolic and diastolic blood pressure,
waist-hip ratio, use of diuretics, and randomized treatment were
tested in the Cox regression models. The effect of changes in uric
acid level during the trial was also assessed. To ensure that changes
in uric acid levels during follow-up did not influence the initial
findings a time-dependent multivariable Cox regression model was
performed. In this model, uric acid levels (as a class variable) and
systolic blood pressure levels (as a continuous variable) were
updated at an annual basis after study baseline. Due to concerns
for close correlation, baseline values of these variables were not
included in the model.
We assessed the proportional hazards assumption both visually
using log-log curves and quantitively testing Schoenfelds residuals
for time-dependency. Model assumptions including linearity,
proportional hazards and interactions were tested and found valid
unless otherwise described. All calculations were done in SAS,
version 9.2 (SAS institute, Cary, North Carolina). The level for
statistical significance was set at a p-value,0.05.
Results
Of the 9,804 subjects who were randomised, 9,742 had serum
uric acid concentration measured at baseline and formed the
population used in the present analyses. The total follow-up
involved 41,195 person years, with an average follow-up time of
4.2 years per subject. There were 816 deaths; 449 (55%) were due
to cardiovascular causes. Overall, 1043 primary outcome events
were reported (355 nonfatal myocardial infarctions, 221 nonfatal
strokes, and 18 resuscitated cardiac arrests). At baseline, 57.6%
were men, 83.6% had diabetes, and 75.1% had CVD; mean6-
standard deviation age, BMI, and SUA were 63.266.1 years,
34.564.5 kg/m2, and 364.7 mmol/l (range 89.0–867.0 mmol/l),
respectively. Demographic and baseline characteristics for sub-
groups defined by gender and quartiles of baseline uric acid
concentrations are shown in Table 1 and 2, respectively.
Increasing baseline uric acid concentration was associated with
increasing age, triglycerides, blood glucose and BMI in both
women and men. Furthermore, increasing baseline uric acid
concentration was associated with greater prevalence of pre-
existing cardiovascular disease in both women and men. There
was a non-linear trend towards differences in the prevalence of
diabetes mellitus between SUA subgroups. Higher baseline uric
acid concentrations were also associated with use of alcohol,
tobacco and in particular diuretics among women and men.
SUA and Cardiovascular Events
In the univariate Cox regression model, there tended to be a J-
shaped relationship between the risk of adverse cardiovascular
events and baseline SUA, with the lowest SUA quartile being the
reference (Table 3). Among women the highest SUA quartile had
a significantly higher risk than the reference (HR: 1.59; 95% CI:
1.20–2.10). The association between time-to-onset of primary
outcome events and the SUA quartiles is further summarized in
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Figure 1 and 2. After more than five years of follow-up, the
proportion of event-free individuals was lowest for the upper SUA
quartile while it was highest for the second lowest SUA quartile
(men: p= 0.05– women: p = 0.001 by the log-rank test). In a model
adjusted only for age, serum creatinine and diuretic use the second
lowest SUA quartile exhibited reduced risk of primary outcome
events relative to the reference group for women (HR: 0.71; 95%
CI: 0.51–0.98) while the increased risk in the highest SUA quartile
exhibited was attenuated from (HR: 1.49; 95% CI: 1.12–1.97) to
(HR: 1.03; 95% CI: 0.75–1.39).
By adding each variable from the large multivariate model to
the age adjusted model one at a time, we found that the increased
risk originally observed in the highest quartile was no longer
significant after adjusting for baseline serum creatinine concen-
tration and use of diuretics. Therefore we created a model
including SUA, age, sex, serum creatinine and diuretic use. In this
model, the most hyperuricemic patients no longer had any
significantly increased risk compared with the lowest quartile
(Table 3), but the reduced risk among women of the second lowest
quartile remained significant (HR: 0.71; 95% CI: 0.51–0.98).
Further adjustment for baseline values of cholesterol, HDL-C,
LDL-C, BMI, glucose, triglycerides, history of congestive heart
failure, history of cardiovascular disease, history of diabetes,
systolic blood pressure, diastolic blood pressure, waist-hip ratio,
tobacco use, alcohol use, and randomized treatment attenuated
these findings further; i.e. among women the second lowest
quartile no longer exhibited reduced risk (HR: 0.73; 95% CI:
0.52–1.01) while the highest quartile exhibited similar risk (HR:
0.99; 95% CI: 0.72–1.36) to the reference group. Similar results
were found for men in the final model (HR: 0.96; 95% CI: 0.77–
1.20) (Table 3).
Looking at cardiovascular death as an isolated outcome, the
association was stronger for the highest quartile than when
considering the combined primary outcome (Table 3). It was only
significant in models 1 and 2 for both women and men. However,
the second quartile in female patients was associated with a lower
risk in all models without obvious attenuation from model 1
through 4 (HR: 0.51; 95% CI: 0.28–0.92).
When analysing SUA as a determinant for acute myocardial
infarction, there were no significant differences between SUA
subgroups (HR: 0.83; 95% CI: 0.60–1.13). The same was the case
for stroke (HR: 0.70; 95% CI: 0.47–1.03), resuscitated cardiac
arrest (HR: 1.70; 95% CI: 0.48–6.04), and cardiovascular death
(HR: 1.24; 95% CI: 0.93–1.64), even when stratifying for gender
(all HRs are comparing the highest SUA quartile with the lowest
SUA quartile in the fully adjusted model).
SUA and All-cause Mortality
When investigating all-cause mortality as an endpoint a signif-
icant interaction between SUA and sex was observed. Therefore
we conducted a sex stratified analysis and demonstrated a stronger
positive relationship between SUA and all-cause mortality in
women (HR: 1.47; 95% CI: 1.02–2.12) than in men (HR: 1.10;
95% CI: 0.85–1.42) for the highest quartile compared with the
lowest in the fully adjusted Cox model; p for interaction= 0.047
(Table 4). The associations between time-to-death and the SUA
quartiles for men and women, respectively, are further summa-
rized in Figure 3 and 4. We also found there was an interaction
between SUA and use of sibutramine. In the placebo group SUA
had no predictive value for all-cause mortality when comparing
the highest and lowest quartiles in the fully adjusted Cox model
(HR: 0.92; 95% CI: 0.70–1.21). In comparison a high level of
SUA was associated with higher risk of all-cause mortality among
patients taking sibutramine when comparing the highest and
lowest quartiles in the fully adjusted Cox model (HR: 1.55; 95%
CI: 1.16–2.07).
Influence of Sibutramine, BMI and Diabetes on Uric Acid
Levels and Primary Outcomes
Use of sibutramine was found to be associated with a mean fall
in uric acid levels as presented in Figure 5. Because of this
potential change of uric acid levels with time we also performed
a time dependent proportional hazard analysis where uric acid was
updated at each yearly visit. This analysis provided similar results
to those described above. Hazard ratios and 95% CIs of the 3
upper quartiles relative to the lowest quartile were: 0.95 (0.75–
1.20), 0.96 (0.76–1.22), and 1.12 (0.90–1.40). These should be
compared to the results of model 4 in Table 3. We investigated for
interactions between use of sibutramine and sex-stratified uric acid
groups and found that they were insignificant (p = 0.55 and 0.81
for all-cause mortality and for the primary endpoint, respectively).
Exploring the relationship between changes in BMI and uric
acid (changes in relation to baseline values), a differential effect of
a loss in BMI was found for the first and second year between
patients with and without diabetes, where patients without
diabetes were found to have greater falls in uric acid for each
1 kg/m2 fall in BMI, compared to patients with diabetes (3.66
standard error [SE] 1.2 mmol/l vs. 2.960.5 mmol/l, p = 0.03 for
year 1; and 6.461.2 mmol/l vs. 3.460.5 mmol/l, p = 0.006 for
Table 1. Baseline characteristics of the study population.
Overall Men Women P-value
Number of patients 9742 5612 4130 ,0.0001
Age (years) 63.2 (6.1) 63.3 (6.1) 63.2 (6.1) 0.58
History of CVD (%) 75.0 83.1 64.0 ,0.0001
Diabetes (%) 83.6 81.5 86.4 ,0.0001
Total Cholesterol
(mmol/l)
194.7 (44.2) 185.8
(41.9)
206.9 (44.3) ,0.0001
Triglycerides (mmol/l) 200.1 (123.0) 205.4
(134.6)
193.0 (104.7) 0.026
Blood glucose
(mmol/l)
8.5 (3.2) 8.4 (3.0) 8.6 (3.3) 0.047
HgbA1c* 7.5 (1.4) 7.5 (1.4) 7.6 (1.5) 0.004
BMI (kg/m2) 34.5 (4.5) 33.6 (4.1) 35.6 (4.8) ,0.0001
Systolic blood
pressure (mmHg)
138.2 (12.7) 137.4
(13.0)
139.3 (12.4) ,0.0001
Diast. blood pressure
(mmHg)
77.8 (8.4) 78.3 (8.4) 77.2 (8.4) ,0.0001
Diuretics users (%) 47.6 44.3 52.1 ,0.0001
Beta-blocker users (%) 61.4 65.1 56.3 ,0.0001
Statin users (%) 66.5 70.5 61.1 ,0.0001
Aspirin users (%) 78.6 85.9 68.6 ,0.0001
Sibutramine users (%) 50.0 49.6 50.5 0.39
Smokers (%) 58.2 74.6 35.9 ,0.0001
Alcohol users (%) 61.6 77.6 39.9 ,0.0001
Primary outcome
event (%)
10.7 12.5 8.2 ,0.0001
All-cause mortality (%) 8.4 9.8 6.5 ,0.0001
Continuous variables are presented as means (SD). Abbreviations: BMI = body
mass index. Diast. = diastolic. P-values were obtained by analysis of variance for
continuous variables and by Cochran-Armitage trend test for discrete variables.
*HbA1c was only measured in diabetics.
doi:10.1371/journal.pone.0059121.t001
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year 2), but not for year 3 and 4 (4.661.3 mmol/l vs.
4.260.6 mmol/l, p = 0.6 for year 3; and 3.961.3 mmol/l vs.
4.660.7 mmol/l, p = 0.6 for year 4).
Discussion
In this population of nearly 10,000 obese/overweight subjects
there was an apparent J-shaped relationship between baseline
SUA and risk of cardiovascular adverse events, but when adjusted
for other cardiovascular risk factors the increased risk for the
highest uric acid quartile was attenuated. The lower risk for the
second lowest quartile remained significant after adjustment for
various confounders among women. This could be because uric
acid is also partly a marker of metabolic state. In this context it is
interesting to notice that an increasing level of SUA is correlated
with many other cardiovascular risk factors such as dyslipidemia
and previous myocardial infarction.
Our previous study investigated the association between
changes in fasting blood glucose and changes in SUA in the four
week lead-in period of the SCOUT trial [17]. The change in SUA
was found to differ according to the presence of diabetes. In
patients with diabetes, a decrease of 1 mmol/L in fasting serum
glucose was associated with only a 1.760.3 mmol/L fall in SUA,
whereas in the non-diabetes group each 1 mmol/L decrease in
fasting blood glucose was associated with a 3.761.5 mmol/L
larger fall in SUA. Sibutramine itself also seemed to promote
a greater fall in uric acid levels than that predicted from weight loss
alone putatively by inhibiting the SLC2A9 uric acid kidney
tubular transporter where uric acid reabsorption also interacts
with glucose reabsorption [17,18]. Thus poorly controlled patients
with diabetes, with higher blood and urinary glucose levels have
a greater fall in blood uric acid levels because of the exchange of
intracellular uric acid for tubular glucose in the apical glucose
transporter part of the SLC2A9 transporter. This could partly
account for our findings of paradoxically increased risk of adverse
outcomes associated with very low uric acid concentrations (if very
low uric acid concentrations were a marker of poor diabetes
control and severe glucosuria). Indeed we could identify an initial
(for the first two years) greater fall in uric acid for each 1 kg/m2
loss in BMI for patients without diabetes, compared with patients
with diabetes.
Because of this effect modifying feature of diabetes we tested for
interactions between both diabetes status and fasting blood glucose
and SUA on the risk of primary outcome. We also would have
liked to test the interaction with HbA1c (generally seen as a better
measure of diabetes control), but this was only measured in
patients with diabetes. However, these interaction tests were all
insignificant, and therefore, we did not stratify further. In the
diabetes group, there was no interaction between HbA1c and
SUA.
We found a gender difference in the impact of SUA on all-cause
mortality. For both genders there was a J-shaped association
between SUA and all-cause mortality, but the increased risk of the
highest uric acid quartile remained significant in the large
multivariate Cox model in women only. Previous studies have
Table 2. Baseline characteristics in men and women stratified by SUA quartiles.
Men Women
Q1 Q2 Q3 Q4 P-value Q1 Q2 Q3 Q4 P-value
Number of patients 1406 1423 1385 1398 1056 1028 1017 1029
Age (years) 62.8 (6.0) 63.3 (6.2) 63.6 (6.2) 63.5 (6.2) 0.004 62.6 (5.9) 63.1 (5.9) 63.1 (6.2) 63.9 (6.2) ,0.0001
History of CVD (%) 77.9 81.5 85.6 87.4 ,0.0001 57.8 63.7 65.0 69.6 ,0.0001
Diabetes (%) 85.4 79.8 79.8 80.8 0.003 86.5 82.3 86.9 90.0 0.002
Total Cholesterol (mmol/l) 184.4 (40.4) 183.8 (41.0) 185.6 (42.0) 189.3 (44.0) 0.002 206.4 (44.1) 207.8 (44.5) 205.9 (44.7) 207.7 (44.0) 0.70
Triglycerides (mmol/l) 195.9 (138.7) 194.8 (124.1) 204.3 (123.3) 226.9 (148.5),0.0001 173.7 (94.2) 181.8 (90.8) 198.5 (119.9) 218.5 (106.3),0.0001
Blood glucose (mmol/l) 9.2 (3.5) 8.3 (2.9) 8.0 (2.7) 8.0 (2.7) ,0.0001 9.2 (3.8) 8.5 (3.4) 8.4 (3.1) 8.3 (3.0) ,0.0001
HgbA1c* 7.9 (1.5) 7.4 (1.3) 7.2 (1.3) 7.2 (1.3) ,0.0001 8.0 (1.6) 7.5 (1.5) 7.4 (1.4) 7.4 (1.4) ,0.0001
BMI (kg/m2) 33.2 (4.0) 33.6 (4.1) 33.7 (4.1) 34.2 (4.2) ,0.0001 34.7 (5.0) 35.2 (4.6) 36.0 (4.7) 36.3 (4.9) ,0.0001
Systolic blood pressure (mmHg) 137.5 (12.5) 137.5 (13.3) 137.5 (12.9) 137.1 (13.1) 0.82 139.5 (12.7) 139.9 (12.1) 139.2 (12.5) 138.6 (12.1) 0.10
Diast. blood pressure (mmHg) 78.3 (8.2) 78.5 (8.5) 78.3 (8.5) 78.1 (8.5) 0.73 77.2 (8.0) 77.7 (8.3) 77.7 (8.4) 76.4 (8.7) 0.0007
Diuretics users (%) 33.0 39.1 43.8 61.5 ,0.0001 36.3 46.0 56.5 70.1 ,0.0001
Beta-blocker users (%) 59.7 64.0 66.1 70.8 ,0.0001 50.4 55.2 57.8 61.8 ,0.0001
Statin users (%) 67.1 70.3 70.8 74.0 ,0.0001 57.9 61.4 62.2 63.0 0.016
Aspirin users (%) 84.0 84.5 87.3 87.9 0.0005 66.1 66.3 68.6 73.6 0.0001
Sibutramine users (%) 49.9 50.0 50.0 48.7 0.57 50.9 48.5 52.1 50.6 0.68
Smokers (%) 70.7 74.9 76.2 76.4 0.0004 30.3 35.9 37.1 40.6 ,0.0001
Alcohol users (%) 75.2 75.0 79.7 80.4 ,0.0001 35.5 39.7 44.0 40.7 0.004
Primary outcome event (%) 12.4 10.9 12.1 14.7 0.035 7.9 6.2 7.3 11.6 0.002
All-cause mortality (%) 8.4 8.6 9.5 12.7 ,0.0001 5.1 4.2 5.5 11.1 ,0.0001
Continuous variables are presented as means (SD). Abbreviations: Q1 = lowest quartile: males: ,317 mmol/l, females: ,280 mmol/l, Q2 = second quartile: males: 317–
373 mmol/l, females: 280–336 mmol/l, Q3 = third quartile: males: 373–432 mmol/l, females: 336–395 mmol/l, Q4 =highest quartile males: .432 mmol/l, females:
.395 mmol/l. BMI = body mass index. Diast. = diastolic.
P-values were obtained by analysis of variance for continuous variables and by Cochran-Armitage trend test for discrete variables.
*HbA1c was only measured in diabetics.
doi:10.1371/journal.pone.0059121.t002
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indicated that loop diuretics may influence uric acid levels. Hence,
loop diuretics rather than uric acid levels may carry an increased
risk of adverse outcomes [19]. This was also observed in our
analyses, where adding creatinine and diuretics to our Cox models
attenuated the estimates.
Table 3. Hazard ratios and 95% confidence intervals for men and women calculated by Cox regression.
Event SUA Model 1 Model 2 Model 3 Model 4
Primary outcome event, men Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 0.87 (0.70–1.08) 0.85 (0.69–1.06) 0.81 (0.65–1.01) 0.84 (0.67–1.05)
Q3 0.99 (0.80–1.22) 0.96 (0.78–1.19) 0.88 (0.71–1.09) 0.90 (0.72–1.11)
Q4 1.22 (1.00–1.50) 1.19 (0.97–1.46) 0.95 (0.76–1.17) 0.96 (0.77–1.20)
Primary outcome event, women Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 0.80 (0.58–1.10) 0.78 (0.56–1.08) 0.71 (0.51–0.98) 0.73 (0.52–1.01)
Q3 0.95 (0.70–1.30) 0.93 (0.68–1.27) 0.78 (0.56–1.07) 0.76 (0.54–1.05)
Q4 1.59 (1.20–2.10) 1.49 (1.12–1.97) 1.03 (0.75–1.39) 0.99 (0.72–1.36)
Cardiovascular death, men Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 1.12 (0.79–1.59) 1.09 (0.77–1.54) 1.01 (0.71–1.43) 1.01 (0.71–1.44)
Q3 1.36 (0.97–1.90) 1.30 (0.93–1.83) 1.13 (0.81–1.59) 1.13 (0.79–1.60)
Q4 1.88 (1.37–2.58) 1.81 (1.32–2.49) 1.28 (0.92–1.79) 1.26 (0.89–1.78)
Cardiovascular death, women Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 0.55 (0.31–0.99) 0.54 (0.30–0.97) 0.48 (0.26–0.86) 0.51 (0.28–0.92)
Q3 0.94 (0.57–1.56) 0.92 (0.55–1.52) 0.74 (0.44–1.24) 0.73 (0.43–1.24)
Q4 2.11 (1.37–3.24) 1.97 (1.28–3.03) 1.28 (0.80–2.04) 1.31 (0.80–2.13)
Cut off points for quartiles: see Table 2. Ref = reference. Hazard ratios (95% confidence intervals). Primary outcome event = AMI, stroke, resuscitation after cardiac arrest
or cardiovascular death.
*Hazard ratios with p-values less than 0.05 are written in bold letters.
Model 1: uric acid.
Model 2: model 1+ age.
Model 3: model 2+ baseline serum creatinine and diuretics use.
Model 4: model 3+ baseline values of cholesterol, HDL-C, LDL-C, BMI, glucose, triglyceride, history of only diabetes/both diabetes and cardiovascular disease/only
cardiovascular disease, history of congestive heart failure, systolic blood pressure, diastolic blood pressure, waist-hip ratio, tobacco use, alcohol use, beta-blocker use,
statin use, aspirin use and sibutramine use.
doi:10.1371/journal.pone.0059121.t003
Figure 1. Proportion of event-free men by SUA quartiles. P-values were calculated using logrank statistics.
doi:10.1371/journal.pone.0059121.g001
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Interestingly, previous data have suggested that uric acid
metabolism is more resistant to the influence of fructose intakes
in women than in men, which could suggest that comparable
elevations in uric acid levels are likely to mirror a rather more
severe metabolic disturbance in women than in men.
Similar results have been obtained by Ong et al. [8] who
investigated SUA as an independent risk factor for cardiovascular
disease and death and all-cause mortality in a cohort of 1294
patients with type 2 diabetes in the Fremantle Diabetes Study.
They did not find that SUA could predict these outcomes after
adjustment for relevant confounders. This was regardless of
whether SUA was considered a continuous or discrete (quartiles)
covariate in the Cox proportional hazard models. In our cohort
more than 80% of subjects had diabetes and the age distribution
was similar to the Freemantle Diabetes Study making the two
studies comparable, though our cohort included a larger pro-
portion of men and was much larger in size.
Our finding of a lack of an independent association between
baseline SUA and primary outcome events is in contrast to several
other studies on uric acid and cardiovascular risk. The American
study NHANES I was a population-based study, including nearly
6000 subjects and with a very long follow-up period of more than
16 years. They found that increased levels of serum uric acid had
a positive relationship to cardiovascular mortality in men and
woman and in both black and white ethnic groups [2]. It should,
however, be emphasized that, although our study population
Figure 2. Proportion of event-free women by SUA quartiles. P-values were calculated using logrank statistics.
doi:10.1371/journal.pone.0059121.g002
Table 4. Hazard ratios and 95% confidence intervals for men and women calculated by Cox regression.
Event SUA Model 1 Model 2 Model 3 Model 4
All-cause mortality, men Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 1.01 (0.78–1.30) 0.96 (0.75–1.24) 0.90 (0.70–1.16) 0.90 (0.69–1.16)
Q3 1.15 (0.90–1.47) 1.08 (0.84–1.39) 0.95 (0.74–1.22) 0.97 (0.75–1.25)
Q4 1.55 (1.23–1.96)* 1.47 (1.16–1.85)* 1.08 (0.85–1.38) 1.10 (0.85–1.42)
All–cause mortality, women Q1 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Q2 0.82 (0.55–1.23) 0.80 (0.54–1.20) 0.74 (0.49–1.10) 0.75 (0.50–1.13)
Q3 1.11 (0.76–1.61) 1.08 (0.73–1.56) 0.93 (0.64–1.35) 0.88 (0.60–1.30)
Q4 2.35 (1.70–3.25)* 2.17 (1.57–3.00)* 1.62 (1.16–2.25)* 1.47 (1.02–2.12)*
Cut off points for quartiles: see Table 2. Ref = reference. Hazard ratios (95% confidence intervals).
*Hazard ratios with p-values less than 0.05 are written in bold letters.
Model 1: uric acid.
Model 2: model 1+ age.
Model 3: model 2+ baseline serum creatinine and diuretics use.
Model 4: model 3+ baseline values of cholesterol, HDL-C, LDL-C, BMI, glucose, triglyceride, history of only diabetes/both diabetes and cardiovascular disease/only
cardiovascular disease, history of congestive heart failure, systolic blood pressure, diastolic blood pressure, waist-hip ratio, tobacco use, alcohol use, beta-blocker use,
statin use, aspirin use and sibutramine use.
doi:10.1371/journal.pone.0059121.t004
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included nearly 10,000 patients at high risk of cardiovascular
events, the myocardial infarction endpoint on its own may have
been underpowered to confirm a true relationship.
In the very large Swedish AMORIS study (n= 417,734) which
was a register based prospective study on AMI, congestive heart
failure (CHF) and stroke in a population without prior cardiovas-
cular disease, a gradual increase in risk of AMI, CHF, and stroke
was found with increasing SUA levels, suggesting that SUA is an
important complementary indicator of cardiovascular risk in the
general population [3]. It is also intriguing that two patient cohorts
[11,12] with different degrees of uric acid lowering with
allopurinol also showed significant reductions in cardiovascular
events with more intensive treatment. This implies that if there is
an independent effect of uric acid evident in large population
studies of reasonably healthy people then the impact of uric acid
per se in patients at high cardiovascular risk is overwhelmed by the
importance of the other metabolic risk factors with which uric acid
increases are associated. However, a more likely explanation is
Figure 3. Kaplan-Meier survival analysis of men by SUA quartiles. P-values were calculated using logrank statistics.
doi:10.1371/journal.pone.0059121.g003
Figure 4. Kaplan-Meier survival analysis of women by SUA quartiles. P-values were calculated using logrank statistics.
doi:10.1371/journal.pone.0059121.g004
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that allopurinol, a xanthine oxidase has other ‘off target’ effects as
shown by its antioxidant properties and its role in increasing
endothelium-dependent vasodilation and prolonging the time to
angina on exercise [20,21].
Strengths of our study included the large number of partici-
pants, and a well-defined cohort of overweight patients. We also
had information on many possible confounders, such as smoking,
BMI, diuretics use, and serum creatinine. However, the present
analysis represents a retrospective evaluation of a prospective
clinical trial and, as a consequence, is subject to the limitations of
such an approach.
A clear limitation is the lack of information on glomerular
filtration rate and serum insulin, since these variables could be
affected in patients with cardiovascular disease, and they can also
affect the level of SUA [22]. We also lacked information on use of
drugs to treat hyperuricemia, such as allopurinol. Further we did
not have information on fructose intake which recently has been
suggested to have a causal influence on uric acid levels (i.e. a high
fructose intake may increase uric acid levels) [23].
We have shown that sibutramine lowers SUA levels [17], but
despite controlling for sibutramine use we cannot fully rule out
a treatment effect on the lack of association between SUA levels
and CV mortality observed in this study.
In conclusion, our study did not show serum uric acid to be an
independent risk factor of cardiovascular events and death in
a population of high cardiovascular risk overweight/obese
subjects. However, our results suggested that SUA was an
independent predictor of all-cause mortality in women.
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